Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: Am Heart J. 2010 Aug;160(2):215–223. doi: 10.1016/j.ahj.2010.03.029

Table 2.

Hypotheses to be tested in FOCUS

Primary Hypothesis:

  • As compared to placebo, the administration of bone marrow mononuclear cells to patients with CAD, LV dysfunction and limiting HF and/or angina will enhance myocardial perfusion, reduce LV end systolic volume, or enhance myocardial oxygen consumption.

Secondary Hypotheses:

  1. As compared to placebo, administration of bone marrow mononuclear cells will enhance regional myocardial function.

  2. As compared to placebo, the administration of bone marrow mononuclear cells will diminish future MACE (new myocardial infarcts and rehospitalization for CHF).

  3. As compared to placebo, administration of bone marrow mononuclear cells will enhance exercise ability.